Of note, GRN (protein name, progranulin) and PSAP (prosaposin) displayed significant differential abundance between all three clinical timepoints (Pre-OP, Post-OP and REC; Fig. 3b) and thus are putative candidate biomarkers of GBM tumour burden, tumour recurrence and treatment resistance. The gene discussed is GRN; the disease is glioblastoma.